Sulfabenz

Sulfabenz

SCHEMBL193566

Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 1.00
KEAP1 Q14145 2/20 0.85
MEN1 O00255 3/20 0.74
ALDH1A1 P00352 2/20 0.74
PKM P14618 1/20 0.74
IL1RN P18510 1/20 0.73
ERAP1 Q9NZ08 1/20 0.73
HTR6 P50406 3/20 0.71
CA2 P00918 5/20 0.70
CA1 P00915 4/20 0.70
CA9 Q16790 4/20 0.70
HTT P42858 1/20 0.70
CA12 O43570 3/20 0.67
POLB P06746 1/20 0.66
PRMT1 Q99873 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
MAPT P10636 1/20 0.62
CYP2C19 P33261 1/20 0.62
TMPRSS6 Q8IU80 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081180 0.92 KEAP1 (1.00) KMT2AKEAP1MEN1ALDH1A1PKM
SCHEMBL11793140 0.90 CA1 (0.85) KMT2AKEAP1MEN1ALDH1A1PKM
SCHEMBL540915 0.90 CA1 (0.85) KMT2AKEAP1MEN1ALDH1A1PKM
SCHEMBL9001182 0.85 KMT2A (1.00) KMT2AKEAP1MEN1ALDH1A1PKM
SCHEMBL25031372 0.85 KEAP1 (1.00) KMT2AKEAP1MEN1ALDH1A1PKM
Phenyl(Phenylsulfonyl)Amine SCHEMBL114765 0.85 KEAP1 (1.00) KMT2AKEAP1MEN1ALDH1A1PKM
Sulfabenzamide SCHEMBL28121834 0.84 KMT2A (0.83) KMT2AKEAP1MEN1ALDH1A1PKM
SCHEMBL19603195 0.84 CA1 (0.76) KMT2AKEAP1MEN1ALDH1A1PKM
SCHEMBL28271812 0.83 HTR6 (1.00) KMT2AKEAP1PKMHTR6CA2
Phenyl(Phenylsulfonyl)Amine SCHEMBL6399560 0.83 KEAP1 (0.95) KMT2AKEAP1MEN1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026097199-A1 SINTERABLE BONDING MATERIAL AND SEMICONDUCTOR DEVICE USING THE SAME HENKEL AG & CO. KGAA (DE) 2026-05-15 WO claimed
CN-118880537-A Anti-biological adhesion warp knitting net product and preparation method thereof 山东海工科技有限公司 2024-11-01 CN claimed
CN-118546213-A Tumor targeting polypeptide and application 南方医科大学深圳医院 2024-08-27 CN claimed
CN-111393304-B Method for preparing p-phenylenediamine from aniline 江苏扬农化工集团有限公司 2023-01-17 CN claimed
US-20220169680-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-06-02 US claimed
EP-3912989-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) 2021-11-24 EP claimed
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 WO claimed
CN-111393304-A Method for preparing p-phenylenediamine from aniline 江苏扬农化工集团有限公司 2020-07-10 CN claimed
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2020-02-13 US claimed
CN-110290790-A For treating composition, the device and method of obsessive-compulsive disorder 消化系统疾病中心 2019-09-27 CN claimed
EP-1054588-A4 METHOD FOR THE STIMULATION OF SPERM PRODUCTION AND GONADAL DEVELOPMENT IN ANIMALS UNIV MARYLAND (US) 2002-09-25 EP claimed
EP-1054588-A1 METHOD FOR THE STIMULATION OF SPERM PRODUCTION AND GONADAL DEVELOPMENT IN ANIMALS UNIVERSITY OF MARYLAND (US) 2000-11-29 EP claimed
WO-1999038376-A1 METHOD FOR THE STIMULATION OF SPERM PRODUCTION AND GONADAL DEVELOPMENT IN ANIMALS UNIVERSITY OF MARYLAND (US) 1999-08-05 WO claimed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP claimed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
EP-0176504-B1 POLYCARBOXYLIC ACID/BORIC ACID/AMINE SALTS AND AQUEOUS SYSTEMS CONTAINING SAME The Lubrizol Corporation (US) 1989-03-22 EP claimed
EP-0036292-B1 PROCESS FOR THE PRODUCTION OF AROMATIC HYDROCARBONS The British Petroleum Company p.l.c. (GB) 1985-01-16 EP claimed
US-4094976-A ANTICOCCIDIAL CYCLICAMINO ETHANOLS AND ESTERS THEREOF MERCK & CO., INC. (US) 1978-06-13 US claimed
US-4011208-A 3-CYANO OR ACYL-4-ARYL-5-ARYLAZO-6-HYDROXYPYRIDONE-2 DYES SANDOZ LTD. (CH) 1977-03-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS GSTK1, GSTO1, GSTM2 KMT2A 3630/4885KEAP1 44/4885MEN1 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.